Imara Inc

NASDAQ:IMRA   3:59:50 PM EDT
2.93
-0.19 (-6.09%)
Products, Regulatory

Imara Announces Interim Analysis Data From Forte Phase 2B Clinical Trial Of Tovinontrine

Published: 11/16/2021 12:43 GMT
Imara Inc (IMRA) - Imara Announces Interim Analysis Data From Forte Phase 2b Clinical Trial of Tovinontrine in Transfusion-dependent Subjects With Beta-thalassemia.
Imara Inc - Tovinontrine Was Generally Well-tolerated in This Patient Population.
Imara Inc - Continuing to Advance Enrollment in Ntdt Cohort of Trial and Expect to Report Initial Ntdt Data in First Half of 2022.